Upadacitinib shows promise in treating severe alopecia areata

Two phase 3 clinical trials involving 1,399 participants aged 12 to 64 have shown that the medication upadacitinib can significantly restore hair in patients with severe alopecia areata. The results, published in JAMA Dermatology, indicate that among those treated with the drug, between 13% and 22.5% achieved complete hair regrowth after 24 weeks. In contrast, recovery rates in placebo groups were substantially lower.

Upadacitinib, commercially known as Rinvoq, is an oral anti-inflammatory and immunosuppressant belonging to the Janus kinase (JAK) inhibitor class. It works by reducing excessive immune system activity that causes inflammation. While primarily used for conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, these trials highlight its efficacy for severe hair loss.

Researchers noted improvements in patients' psychosocial well-being and quality of life due to the treatment. However, while serious side effects were recorded in a small proportion of participants, the study's 24-week duration means further research is required to determine long-term risks and sustained success.